A double-blind, placebo controlled, crossover trial of carbamazepine in overactive, severely mentally handicapped patients.
A double-blind, placebo controlled, crossover trial of carbamazepine in 12 severely and profoundly mentally retarded, overactive adult patients is described. The trial lasted 7 months and those patients in whom overactivity was the dominant problem responded to some degree to carbamazepine with a reduction in overactivity. This was particularly so in patients in whom overactivity was accompanied by some elevation of mood. Patients in whom overactivity was part of a wider spectrum of multiple behaviour disorders showed a scatter of responses. There was no relationship between response to carbamazepine and the presence or absence of epilepsy. The trial identified a small group of mentally retarded patients in whom carbamazepine might be clinically useful.
D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002220:Carbamazepine / Q000097:blood / Q000627:therapeutic use*; D004311:Double-Blind Method; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy*; D008607:Intellectual Disability / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D002220:Carbamazepine